Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MEDIFAST INCMED · Entity 6587 | Director | September 28, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MEDIFAST INC
Report date September 28, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Dan and Allyson Family Irrevocable Trust | 130,609.352 |
Last balance in matching sequence
After 2026-09-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-28 · Sale · Disposed 9,545 · Balance 140,153.352 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.900 to $12.125, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Row 2 · 2026-09-29 · Sale · Disposed 9,544 · Balance 130,609.352 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.670 to $11.810, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. |
| Common StockSEC Table I · non-derivative | IndirectDan and Allyson as Joint Tenants | 17,678 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,678 F4: These shares are directly owned by a joint account of which the reporting person owns as a joint tenant with his spouse. |
| Common StockSEC Table I · non-derivative | Direct | 188,233 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 188,233 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.900 to $12.125, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.670 to $11.810, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These shares are directly owned by a joint account of which the reporting person owns as a joint tenant with his spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 802 | $267.00 | $214,134.88 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 8 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,326 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F9 · price: This transaction was executed in multiple trades at prices ranging from $266.66 USD to $267.54 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 287 | $265.29 | $76,137.91 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 7 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,128 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F8 · price: This transaction was executed in multiple trades at prices ranging from $265.10 USD to $265.79 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 213 | $264.35 | $56,305.55 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 6 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,415 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F7 · price: This transaction was executed in multiple trades at prices ranging from $264.10 USD to $265.07 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 863 | $263.31 | $227,238.60 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 5 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,628 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F6 · price: This transaction was executed in multiple trades at prices ranging from $263.00 USD to $263.48 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 600 | $262.54 | $157,524.00 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 4 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,491 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F5 · price: This transaction was executed in multiple trades at prices ranging from $262.00 USD to $262.96 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,000 | $261.46 | $261,456.00 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,091 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F4 · price: This transaction was executed in multiple trades at prices ranging from $260.94 USD to $261.92 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,000 | $260.37 | $260,373.80 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,091 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $259.83 USD to $260.82 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:18 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 600 | $259.32 | $155,593.50 |
DisclosureSEC source: 0001562180-21-004412 · primarydocument.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,091 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $258.74 USD to $259.66 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 100 | $279.03 | $27,903.00 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 17 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,691 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 767 | $277.32 | $212,706.36 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 16 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,791 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F17 · price: This transaction was executed in multiple trades at prices ranging from $276.86 USD to $277.81 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,019 | $276.35 | $281,605.34 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 15 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,558 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F16 · price: This transaction was executed in multiple trades at prices ranging from $275.85 USD to $276.79 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 681 | $275.12 | $187,358.63 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 14 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,577 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F15 · price: This transaction was executed in multiple trades at prices ranging from $274.75 USD to $275.66 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 700 | $274.13 | $191,888.76 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 13 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,258 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F14 · price: This transaction was executed in multiple trades at prices ranging from $273.68 USD to $274.61 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,410 | $273.03 | $384,975.26 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 12 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,958 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F13 · price: This transaction was executed in multiple trades at prices ranging from $272.59 USD to $273.58 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 947 | $272.13 | $257,704.27 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 11 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,368 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F12 · price: This transaction was executed in multiple trades at prices ranging from $271.58 USD to $272.56 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 200 | $270.49 | $54,097.60 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 10 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,315 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F11 · price: This transaction was executed in multiple trades at prices ranging from $270.25 USD to $270.59 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 421 | $284.03 | $119,577.98 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 9 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,515 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $283.47 USD to $284.45 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 811 | $282.92 | $229,450.15 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 8 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,936 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $282.42 USD to $283.37 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 3,514 | $281.83 | $990,342.19 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 7 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,747 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $281.34 USD to $282.30 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 700 | $280.89 | $196,622.65 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 6 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,261 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $280.25 USD to $281.21 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 548 | $279.48 | $153,157.34 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 5 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,961 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $279.03 USD to $280.00 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 752 | $278.40 | $209,360.11 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 4 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,509 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $278.03 USD to $279.02 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 200 | $276.73 | $55,346.00 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,261 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $276.57 USD to $276.89 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 450 | $275.84 | $124,128.05 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,461 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $275.47 USD to $276.32 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:32 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 300 | $274.51 | $82,353.39 |
DisclosureSEC source: 0001104659-21-082800 · tm2120119d1_4seq1.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,911 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $274.23 USD to $274.80 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 100 | $291.00 | $29,100.00 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 17 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,211 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 343 | $289.28 | $99,223.69 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 16 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,311 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F16 · price: This transaction was executed in multiple trades at prices ranging from $289.00 USD to $289.49 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 100 | $287.78 | $28,777.66 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 15 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,654 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F15 · price: This transaction was executed in multiple trades at prices ranging from $287.68 USD to $287.89 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 100 | $285.74 | $28,574.36 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 14 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,754 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F14 · price: This transaction was executed in multiple trades at prices ranging from $285.65 USD to $286.01 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 100 | $284.65 | $28,465.00 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 13 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,854 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 300 | $283.67 | $85,099.95 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 12 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,954 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F13 · price: This transaction was executed in multiple trades at prices ranging from $283.45 USD to $284.00 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 303 | $282.06 | $85,464.00 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 11 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,254 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F12 · price: This transaction was executed in multiple trades at prices ranging from $282.00 USD to $282.10 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,038 | $281.44 | $292,137.63 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 10 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,557 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F11 · price: This transaction was executed in multiple trades at prices ranging from $281.00 USD to $281.94 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,907 | $280.30 | $534,537.63 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 9 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,595 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $279.85 USD to $280.83 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 2,267 | $279.56 | $633,763.20 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 8 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,502 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $278.85 USD to $279.84 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 521 | $278.14 | $144,911.20 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 7 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,769 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $277.85 USD to $278.83 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 400 | $293.11 | $117,245.76 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 6 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,290 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $292.67 USD to $293.32 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 201 | $291.61 | $58,613.31 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 5 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,690 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $291.30 USD to $291.74 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 761 | $290.88 | $221,356.48 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 4 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,891 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $290.25 USD to $291.16 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,563 | $289.30 | $452,177.46 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,652 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $288.92 USD to $289.88 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 3,264 | $288.21 | $940,723.32 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,215 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $287.86 USD to $288.53 USD inclusive; the price reported above reflects the weighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | MEDIFAST INC MED · Entity 6587 | SaleCommon Stock | 1,847 | $287.41 | $530,840.91 |
DisclosureSEC source: 0001104659-21-081619 · tm2119857d1_4seq1.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,479 F1 · shares: The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $286.86 USD to $287.85 USD inclusive; the price reported above reflects theweighted average sale price. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 22:18 UTC | MEDIFAST INC MED · Entity 6587 | GrantCommon Stock | 5,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-039259 · tm2110392d1_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,326 F1 · shares: Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:41 UTC | MEDIFAST INC MED · Entity 6587 | Tax withholdingCommon Stock | 1.309 | $268.23 | $351.11 |
DisclosureSEC source: 0001104659-21-026923 · tm217757d2_4.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,831 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:41 UTC | MEDIFAST INC MED · Entity 6587 | Tax withholdingCommon Stock | 1.841 | $268.23 | $493.81 |
DisclosureSEC source: 0001104659-21-026923 · tm217757d2_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,140 Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 23:53 UTC | MEDIFAST INC MED · Entity 6587 | Tax withholdingCommon Stock | 1,348 | $101.45 | $136,754.60 |
DisclosureSEC source: 0001104659-20-024003 · tm209709d2_4.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,974 Read SEC document |
| February 20, 2020 Filed Apr 22, 2020 23:16 UTC Amendment | MEDIFAST INC MED · Entity 6587 | Tax withholdingCommon Stock | 1.348 | $101.45 | $136.75 |
DisclosureSEC source: 0001104659-20-049818 · tm2016674d1_4.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,981 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 23:53 UTC | MEDIFAST INC MED · Entity 6587 | GrantCommon Stock | 10,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-024003 · tm209709d2_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,142 F1 · shares: Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 19, 2020 Filed Apr 22, 2020 23:16 UTC Amendment | MEDIFAST INC MED · Entity 6587 | GrantCommon Stock | 11,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-049818 · tm2016674d1_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,329 F1 · shares: The amount of securities acquired on February 19, 2020 was erroneously reported as 10,172 in the original Form 4 filed on February 21, 2020. This error impacted total beneficial ownership in this form. This amendment is being filed to include 1,187 erroneously omitted from the reporting person's Form 4 as originally filed. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:35 UTC | MEDIFAST INC MED · Entity 6587 | Exercise / conversionPerformance Stock Units · Derivative | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000138 · primarydocument.xml · derivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 210,000 Performance Stock Units were granted on December 3, 2016, and vested on December 31, 2019 and converted into common stock on a one-for-one basis. F1 · derivative.exercise_date: 210,000 Performance Stock Units were granted on December 3, 2016, and vested on December 31, 2019 and converted into common stock on a one-for-one basis. F1 · derivative.expiration_date: 210,000 Performance Stock Units were granted on December 3, 2016, and vested on December 31, 2019 and converted into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.